Referenzen
Produkte Transfektion
Kostenlose Testsamples
Anwendungshinweise:
Im „Transfection Reagent Selection Guide“ können Sie durch Filterfunktionen z.B. für Ihre Kombination aus zu transfizierender Zelle und Nukleinsäure die Liste vorhandener Referenzen durchsuchen. Ebenso können Sie im Feld „Referenzen durchsuchen“ am Anfang der Seite mit passenden Schlagwörtern zu einem Ergebnis gelangen. Eine Referenz zeigt an, dass das gefundene Transfektionsreagenz bereits erfolgreich für die entsprechende Anwendung verwendet wurde. Im Idealfall sind getestete Transfektionsparameter und Transfektionseffizienzen angegeben.
Keine Referenz? > Allgemeine Auswahlhilfe
Wenn Sie keine Referenz gefunden haben, heißt das nicht, dass kein passendes Reagenz zur Verfügung steht, sondern lediglich, dass bisher keine Erfahrungsberichte vorliegen. In diesem Falle kann durch eine Vorauswahl ein erfolgsversprechendes Transfektionsreagenz ausgewählt (Allgemeine Auswahlhilfe) und letztendlich ausgetestet (Kostenlose Testsamples) werden. Wenn Sie einen Erfahrungsbericht für uns schreiben möchten machen wir Ihnen ein Angebot für eine Gegenleistung.
CELL TYPE | DESCRIPTION OF CELL TYPE | CAT.NO. | SPECIES | ORIGIN OF CELLS | COMMON CELL TYPE | GROWTH PROPERTIES | NUCLEIC ACID / DELIVERED MOLECULE | APPLICATION | PRODUCT | REFERENCE TYPE | BIBLIOGRAPHIC DATA | LINK | |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|
HBL 100 |
Human transformed epithelial cell line | Human | breast | cell line | adherent | siRNA | cotransfection (plasmid/siRNA) | Metafectene PRO | publication | A. M. Scherbakov et al., Exp. Cell Res., 2013, 319: 3150 – 3159, doi.org/10.1016/j.yexcr.2013.08.019 | |||
HBL 100 |
Human transformed epithelial cell line | Human | breast | cell line | adherent | siRNA | RNA-Interference | Metafectene PRO | publication | A. M. Scherbakov et al., Exp. Cell Res., 2013, 319: 3150 – 3159, doi.org/10.1016/j.yexcr.2013.08.019 | |||
hBMSC |
Human bone marrow-derived mesenchymal stem cells | Human | bone | primary cell | adherent | siRNA | RNA-Interference | Metafectene PRO | publication | E. J. Lee et al., Mol. Therapy, 2017, 26(3): 845-859, doi.org/10.1016/j.ymthe.2017.12.015 | Link | ||
hBMSC |
Human bone marrow-derived mesenchymal stem cells | Human | bone | stem cell | adherent | siRNA | Metafectene PRO | publication | E. J. Lee, Mol. Therapy, 2018, doi: 10.1016/j.ymthe.2017.12.015 | ||||
hCMEC/D3 |
Human brain-derived microvascular endothelial cells | Human | brain | cell line | adherent | siRNA | RNA-Interference | Metafectene PRO | publication | S. Krishnan et al.,Oncotarget, 2015, 6(26): 22480-22495 | Link | ||
HCT116 |
Human colon adenocarcinoma cell line | ATCC CCL-247 | Human | digestive organs | cell line | adherent | siRNA | RNA-Interference | Metafectene PRO | publication | M. Mannefeld et al., Cancer Res., May 2009; 69: 4073 - 4080 | Link | |
HCT116 |
Human colon adenocarcinoma cell line | ATCC CCL-247 | Human | digestive organs | cell line | adherent | siRNA | RNA-Interference | Metafectene PRO | publication | J. Galán‐Martínez et al., Mol. Oncology, 2021, doi:10.1002/1878-0261.13085 | Link | |
HCT116 p53 -/- |
Human colon adenocarcinoma cell line deficient of p53 | Human | digestive organs | cell line | adherent | siRNA | RNA-Interference | Metafectene PRO | publication | C. Ren et al., J. Biol. Chem., Apr 2016; 291: 9629 - 9637 | Link | ||
HD-11 |
Chicken leukaemic macrophage cell line | Chicken | immune system | cell line | adherent | siRNA | RNA-Interference | Metafectene PRO | publication | H. Berberich et al., FEBS Open Bio, 2017, 7: 1909–1923, doi:10.1002/2211-5463.12323 | Link | ||
HEK/DOR |
Human embryonic kidney cell line stably expressing DOR (derivat of HEK293) | Human | urinary system | cell line | adherent | siRNA | RNA-Interference | Metafectene PRO | publication | D. A. Eisinger et al., J. Biol. Chem., Dec 2009; 284: 34819 - 34828 | Link | ||
HEK293 |
Human embryonic kidney cell line | ATCC CRL-1573 | Human | urinary system | cell line | adherent | siRNA | RNA-Interference | Metafectene PRO | application note | ![]() |
||
HEK293 |
Human embryonic kidney cell line | ATCC CRL-1573 | Human | urinary system | cell line | adherent | siRNA | RNA-Interference | Metafectene PRO | publication | E. Werwein et al., Nucleic Acids Res., 2019, Vol. 47, 1: 103–121, doi: 10.1093/nar/gky935 | Link | |
HEK293 |
Human embryonic kidney cell line | ATCC CRL-1573 | Human | urinary system | cell line | adherent | siRNA | RNA-Interference | Metafectene PRO | publication | E. Werwein et al., Nucleic Acids Res., 2019, 47(1): 103–121, doi: 10.1093/nar/gky935 | Link | |
HEK293 |
Human embryonic kidney cell line | ATCC CRL-1573 | Human | urinary system | cell line | adherent | siRNA | RNA-Interference | Metafectene PRO | publication | S. Kim et al., Nature Communications, 2019, 10:4898, doi.org/10.1038/s41467-019-12910-2 | Link | |
HeLa |
Human cervix adenocarcinoma cell line | ATCC CCL-2 | Human | genital tract | cell line | adherent | siRNA | RNA-Interference | Metafectene PRO | publication | P. Wolter et al., J. Cell Sci., May 2012; 125: 2393 - 2406 | Link | |
HeLa |
Human cervix adenocarcinoma cell line | ATCC CCL-2 | Human | genital tract | cell line | adherent | siRNA | RNA-Interference | Metafectene PRO | publication | P. Hubel et al., Nature Immunology, 2019, 20: 493–502, https://doi.org/10.1038/s41590-019-0323-3. | Link | |
HeLa |
Human cervix adenocarcinoma cell line | ATCC CCL-2 | Human | genital tract | cell line | adherent | siRNA | RNA-Interference | Metafectene PRO | publication | K. Klement et al., J. Cell Biol., Dec 2014; 207: 717 - 733 | Link | |
HeLa |
Human cervix adenocarcinoma cell line | ATCC CCL-2 | Human | genital tract | cell line | adherent | siRNA | RNA-Interference | Metafectene PRO | publication | L. Wedeken et al., J. Biol. Chem., Dec 2011; 286: 42855 - 42862. | Link | |
HeLa |
Human cervix adenocarcinoma cell line | ATCC CCL-2 | Human | genital tract | cell line | adherent | siRNA | RNA-Interference | Metafectene PRO | publication | D. Marotta, PhD Thesis, 2015, University College London | Link | |
HeLa |
Human cervix adenocarcinoma cell line | ATCC CCL-2 | Human | genital tract | cell line | adherent | siRNA | RNA-Interference | Metafectene PRO | application note | ![]() |
||
HeLa |
Human cervix adenocarcinoma cell line | ATCC CCL-2 | Human | genital tract | cell line | adherent | siRNA | RNA-Interference | Metafectene PRO | publication | E. Pesarchuk, 2016, Dissertation, Universtity of Vancouver | Link | |
HeLa |
Human cervix adenocarcinoma cell line | ATCC CCL-2 | Human | genital tract | cell line | adherent | siRNA | RNA-Interference | Metafectene PRO | publication | S. Cohen et al., Biochim. et Biophysica Acta, 2013, 1833: 1104–1113, doi.org/10.1016/j.bbamcr.2012.12.021 | Link | |
HepG2 |
Human hepatocellular carcinoma cell line | ATCC HB-8065 | Human | digestive organs | cell line | adherent | siRNA | RNA-Interference | Metafectene PRO | publication | C. Ullio et al., J. Lipid Res., Jun 2012; 53: 1134 - 1143 | Link | |
HepG2 |
Human hepatocellular carcinoma cell line | ATCC HB-8065 | Human | digestive organs | cell line | adherent | siRNA | RNA-Interference | Metafectene PRO | publication | O. Pellerito et al., Mol. Pharmacol., May 2010; 77: 854 - 863 | Link | |
HepG2 |
Human hepatocellular carcinoma cell line | ATCC HB-8065 | Human | digestive organs | cell line | adherent | siRNA | cotransfection (plasmid/siRNA) | Metafectene PRO | publication | F. Damiano et al., Biochem. J., 2013, 449: 543–553, doi:10.1042/BJ20120906 |